Last reviewed · How we verify

Polidocanol foam sclerotherapy

Universidade do Porto · Phase 2 active Small molecule

Polidocanol foam sclerotherapy is a Small molecule drug developed by Universidade do Porto. It is currently in Phase 2 development. Also known as: Aethoxysklerol 3%).

At a glance

Generic namePolidocanol foam sclerotherapy
Also known asAethoxysklerol 3%)
SponsorUniversidade do Porto
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Polidocanol foam sclerotherapy

What is Polidocanol foam sclerotherapy?

Polidocanol foam sclerotherapy is a Small molecule drug developed by Universidade do Porto.

Who makes Polidocanol foam sclerotherapy?

Polidocanol foam sclerotherapy is developed by Universidade do Porto (see full Universidade do Porto pipeline at /company/universidade-do-porto).

Is Polidocanol foam sclerotherapy also known as anything else?

Polidocanol foam sclerotherapy is also known as Aethoxysklerol 3%).

What development phase is Polidocanol foam sclerotherapy in?

Polidocanol foam sclerotherapy is in Phase 2.

Related